A. Bohan and J. B. Peter, Polymyositis and dermatomyositis, New England Journal of Medicine, vol.292, issue.7, pp.344-347, 1975.

J. E. Hoogendijk, A. A. Amato, and B. R. Lecky, 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscular Disorders, vol.14, issue.5, pp.337-345, 2003.

R. D. Sontheimer, Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?, Journal of the American Academy of Dermatology, vol.46, issue.4, pp.626-636, 2002.

M. Best, M. Jachiet, and N. Molinari, Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients, Journal of the European Academy of Dermatology and Venereology, vol.32, issue.7, pp.1164-1172, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01821363

M. Cruellas, V. S. Viana, M. Levy-neto, F. H. Souza, and S. K. Shinjo, Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis, Clinics, vol.68, issue.7, pp.909-914, 2013.

M. Satoh, S. Tanaka, A. Ceribelli, S. J. Calise, and E. K. Chan, A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy, Clinical Reviews in Allergy & Immunology, vol.52, issue.1, pp.1-19, 2017.

L. Bodoki, M. Nagy-vincze, Z. Griger, Z. Betteridge, L. Szöll?si et al., Four dermatomyositis-specific autoantibodies-anti-TIF1?, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort, Autoimmunity Reviews, vol.13, issue.12, pp.1211-1219, 2014.

Y. Hamaguchi, M. Kuwana, and K. Hoshino, Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study, Archives of Dermatology, vol.147, issue.4, pp.391-398, 2011.

M. Fujimoto, A. Murakami, and S. Kurei, Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis, Journal of Dermatological Science, vol.84, issue.3, pp.272-281, 2016.

H. Yang, Q. Peng, and L. Yin, Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study, Arthritis Research & Therapy, vol.19, issue.1, p.259, 2017.

E. Trallero-araguás and J. Á. Rodrigo-pendás,

A. Selva-o'callaghan, Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis, Arthritis & Rheumatism, vol.64, issue.2, pp.523-532, 2012.

A. Hida, T. Yamashita, and Y. Hosono, Anti-TIF1-? antibody and cancer-associated myositis: a clinicohistopathologic study, Neurology, vol.87, issue.3, pp.299-308, 2016.

M. Fujimoto, Y. Hamaguchi, and K. Kaji, Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins, Arthritis & Rheumatism, vol.64, issue.2, pp.513-522, 2012.

S. Sato, M. Hirakata, and M. Kuwana, Autoantibodies to a 140-kd polypeptide, CADM-140, Arthritis & Rheumatism, vol.52, issue.5, pp.1571-1576, 2005.

J. C. Hall, L. Casciola-rosen, and L. A. Samedy, Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum, Arthritis Care and Research, vol.65, issue.8, pp.1307-1315, 2013.

D. Fiorentino, L. Chung, J. Zwerner, A. Rosen, and L. Casciola-rosen, The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study, Journal of the American Academy of Dermatology, vol.65, issue.1, pp.25-34, 2011.

K. Hoshino, Y. Muro, K. Sugiura, Y. Tomita, R. Nakashima et al., Anti-MDA5 and anti-TIF1-? antibodies have clinical significance for patients with dermatomyositis, Rheumatology, vol.49, issue.9, pp.1726-1733, 2010.

T. Koga, K. Fujikawa, and Y. Horai, The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM, Rheumatology, vol.51, issue.7, pp.1278-1284, 2012.

F. Chen, S. Li, T. Wang, J. Shi, and G. Wang, Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies, The American Journal of the Medical Sciences, vol.355, issue.1, pp.48-53, 2018.

Z. Chen, M. Cao, and M. N. Plana, Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis, Arthritis Care & Research, vol.65, issue.8, pp.1316-1324, 2013.

E. H. Kang, R. Nakashima, and T. Mimori, Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis, BMC Musculoskeletal Disorders, vol.11, issue.1, p.223, 2010.

T. Matsushita, K. Mizumaki, and M. Kano, Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis, The British Journal of Dermatology, vol.176, issue.2, pp.395-402, 2017.

T. Gono, S. Sato, and Y. Kawaguchi, Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Rheumatology, vol.51, issue.9, pp.1563-1570, 2012.

R. Aggarwal, L. G. Rider, and N. Ruperto, American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative, Annals of the Rheumatic Diseases, vol.76, issue.5, pp.792-801, 2016.

L. Li, Q. Wang, and X. Wen, Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease, Oncotarget, vol.8, issue.44, pp.76129-76140, 2017.

S. Moghadam-kia, C. V. Oddis, S. Sato, M. Kuwana, and R. Aggarwal, Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis, Arthritis Care & Research, vol.68, issue.5, pp.689-694, 2016.

J. Li, Y. Liu, and Y. Li, Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis, The Journal of Dermatology, vol.45, issue.1, pp.46-52, 2018.

Y. Kimura, F. Sakai, and O. Nakano, The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains, Journal of Biological Chemistry, vol.277, issue.23, pp.20611-20617, 2002.

C. V. Oddis, N. Fertig, and A. Goel, Clinical and serological characterization of the anti-MJ antibody in childhood myositis, Arthritis & Rheumatism, vol.40, issue.9, p.139, 1997.

A. Ceribelli, M. Fredi, and M. Taraborelli, Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis, Arthritis Research & Therapy, vol.14, issue.2, p.97, 2012.

Y. Ichimura, T. Matsushita, and Y. Hamaguchi, Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy, Annals of the Rheumatic Diseases, vol.71, issue.5, pp.710-713, 2012.

M. Fredi, F. Bartoli, and I. Cavazzana, Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options, Clinical and Experimental Rheumatology, vol.35, issue.2, pp.303-308, 2017.

H. Yang, X. Lu, and Q. Peng, Differential clinical associations of anti-nuclear matrix protein 2 autoantibodies in patients with idiopathic inflammatory myopathies, Arthritis & Rheumatology, vol.70, issue.8, pp.1288-1297, 2018.

D. F. Fiorentino, L. S. Chung, and L. Christopher-stine, Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?, Arthritis & Rheumatism, vol.65, issue.11, pp.2954-2962, 2013.

K. Komura, M. Fujimoto, and T. Matsushita, Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis, Journal of Dermatological Science, vol.40, issue.3, pp.215-217, 2005.

N. Ikeda, K. Takahashi, Y. Yamaguchi, M. Inasaka, M. Kuwana et al., Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients, The Journal of Dermatology, vol.38, issue.10, pp.973-979, 2011.

Z. E. Betteridge, H. Gunawardena, and H. Chinoy, Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1621-1625, 2009.

E. Tarricone, A. Ghirardello, M. Rampudda, N. Bassi, L. Punzi et al., Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort, Journal of Immunological Methods, vol.384, issue.1-2, pp.128-134, 2012.

M. Fujimoto, T. Matsushita, and Y. Hamaguchi, Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort, Annals of the Rheumatic Diseases, vol.72, issue.1, pp.151-153, 2013.

Y. Muro, K. Sugiura, and M. Akiyama, Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients, Autoimmunity, vol.46, issue.4, pp.279-284, 2013.

Y. Ge, X. Lu, X. Shu, Q. Peng, and G. Wang, Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts, Scientific Reports, vol.7, issue.1, p.188, 2017.

I. N. Targoff, Autoantibodies in polymyositis, Rheumatic Diseases Clinics of North America, vol.18, issue.2, pp.455-482, 1992.

H. Hozumi, N. Enomoto, and M. Kono, Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study, PLoS One, vol.10, issue.3, p.120313, 2015.

J. Shi, S. Li, and H. Yang, Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies, The Journal of Rheumatology, vol.44, issue.7, pp.1051-1057, 2017.

R. Aggarwal, E. Cassidy, and N. Fertig, Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients, Annals of the Rheumatic Diseases, vol.73, issue.1, pp.227-232, 2014.

C. A. Dinarello, D. Novick, S. Kim, and G. Kaplanski, Interleukin-18 and IL-18 binding protein, Frontiers in Immunology, vol.4, p.289, 2013.

M. Tucci, C. Quatraro, F. Dammacco, and F. Silvestris, Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies, Clinical and Experimental Immunology, vol.146, issue.1, pp.21-31, 2006.

T. Gono, Y. Kawaguchi, and T. Sugiura, Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease, Rheumatology, vol.49, issue.10, pp.1878-1881, 2010.

Y. Yang, G. Yin, J. Hao, Q. Xie, and Y. Liu, Serum interleukin-18 level is associated with disease activity and interstitial lung disease in patients with dermatomyositis, Archives of Rheumatology, vol.32, issue.3, pp.181-188, 2017.

H. Shen, L. Xia, and J. Lu, Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases, Cytokine, vol.60, issue.2, pp.334-337, 2012.

Y. Muro, K. Sugiura, and M. Akiyama, Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Clinical Rheumatology, vol.32, issue.3, pp.395-398, 2013.

J. Zou, J. Chen, Q. Yan, Q. Guo, and C. Bao, Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease, Clinical Rheumatology, vol.35, issue.1, pp.117-125, 2016.

T. A. Fehniger and M. A. Caligiuri, Interleukin 15: biology and relevance to human disease, Blood, vol.97, issue.1, pp.14-32, 2001.

P. Mielnik, H. Chwalinska-sadowska, E. Wiesik-szewczyk, W. Maslinski, and M. Olesinska, Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity, Rheumatology International, vol.32, issue.3, pp.639-643, 2012.

J. Suzuki, S. Morimoto, H. Amano, Y. Tokano, Y. Takasaki et al., Serum levels of interleukin 15 in patients with rheumatic diseases, The Journal of Rheumatology, vol.28, issue.11, pp.2389-2391, 2001.

T. Sugiura, M. Harigai, and Y. Kawaguchi, Increased IL-15 production of muscle cells in polymyositis and dermatomyositis, International Immunology, vol.14, issue.8, pp.917-924, 2002.

M. Zong, I. Loell, and E. Lindroos, Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor ? expression in muscle tissue of patients with polymyositis or dermatomyositis, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.1055-1063, 2012.

L. S. Quinn, K. L. Haugk, and K. H. Grabstein, Interleukin-15: a novel anabolic cytokine for skeletal muscle, Endocrinology, vol.136, issue.8, pp.3669-3672, 1995.

G. Chevrel, G. Page, C. Granet, N. Streichenberger, A. Varennes et al., Interleukin-17 increases the effects of IL-1? on muscle cells: arguments for the role of T cells in the pathogenesis of myositis, Journal of Neuroimmunology, vol.137, issue.1-2, pp.125-133, 2003.

H. Shen, L. Xia, J. Lu, and W. Xiao, Interleukin-17 and interleukin-23 in patients with polymyositis and 12 Journal of Immunology Research dermatomyositis, Scandinavian Journal of Rheumatology, vol.40, issue.3, pp.217-220, 2011.

T. Kishimoto, S. Kang, and T. Tanaka, IL-6: a new era for the treatment of autoimmune inflammatory diseases, pp.131-147, 2015.

T. Gono, H. Kaneko, and Y. Kawaguchi, Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease, vol.53, pp.2196-2203, 2014.

H. Bilgic, S. R. Ytterberg, and S. Amin, Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis, Arthritis & Rheumatism, vol.60, issue.11, pp.3436-3446, 2009.

M. Yang, X. Cen, Q. Xie, C. Zuo, G. Shi et al., Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis, Clinical and Developmental Immunology, vol.2013, 2013.

H. Kawasumi, T. Gono, and Y. Kawaguchi, IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis, BioMed Research International, vol.2014, 2014.

T. Kotani, T. Takeuchi, and T. Ishida, Increased serum LIGHT levels correlate with disease progression and severity of interstitial pneumonia in patients with dermatomyositis: a case control study, PLoS One, vol.10, issue.10, p.140117, 2015.

A. M. Reed, E. Peterson, and H. Bilgic, Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course, Arthritis & Rheumatism, vol.64, issue.12, pp.4078-4086, 2012.

M. Nara, A. Komatsuda, and A. Omokawa, Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease, Modern Rheumatology, vol.24, issue.4, pp.633-636, 2014.

H. Yoshida and C. A. Hunter, The immunobiology of interleukin-27, Annual Review of Immunology, vol.33, issue.1, pp.417-443, 2015.

G. Shahryari, A. Shahraki, and Z. Zakeri, Serum levels of interleukin-27 and interleukin-33 in patients with dermatomyositis and polymyositis compared to healthy control subjects, Gene, Cell and Tissue, vol.2, issue.4, p.31087, 2015.

J. Choi, P. S. Leung, C. Bowlus, and M. E. Gershwin, IL-35 and autoimmunity: a comprehensive perspective, Clinical Reviews in Allergy & Immunology, vol.49, issue.3, pp.327-332, 2015.

H. F. Mann, H. Hulejova, and J. Zámecník, Interleukin-35 in idiopathic inflammatory myopathies, Annals of the Rheumatic Diseases, vol.75, p.1109, 2016.

L. Yin, Y. Ge, and H. Yang, The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis, Clinical Rheumatology, vol.35, issue.11, pp.2715-2721, 2016.

S. Salomonsson and I. E. Lundberg, Cytokines in idiopathic inflammatory myopathies: review, Autoimmunity, vol.39, issue.3, pp.177-190, 2006.

C. Bossen and P. Schneider, BAFF, APRIL and their receptors: structure, function and signaling, vol.18, pp.263-275, 2006.

M. Chen, X. Lin, and Y. Liu, The function of BAFF on T helper cells in autoimmunity, Cytokine & Growth Factor Reviews, vol.25, issue.3, pp.301-305, 2014.

O. Krystufkova, T. Vallerskog, and S. B. Helmers, Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.836-843, 2009.

Q. Peng, X. M. Shu, D. X. Wang, Y. Wang, X. Lu et al., B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis, Biomarkers in Medicine, vol.8, issue.3, pp.395-403, 2014.

C. M. De-padilla, K. T. Mcnallan, and C. S. Crowson, BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies, The Journal of Rheumatology, vol.40, issue.3, pp.294-302, 2013.

A. Baek, H. J. Park, and S. J. Na, The expression of BAFF in the muscles of patients with dermatomyositis, Journal of Neuroimmunology, vol.249, issue.1-2, pp.96-100, 2012.

X. Shu, Q. Peng, X. Lu, and G. Wang, HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis/dermatomyositis with interstitial lung disease, PLoS One, vol.11, issue.8, p.161436, 2016.

M. Zong, J. D. Bruton, and C. Grundtman, TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis, Annals of the Rheumatic Diseases, vol.72, issue.8, pp.1390-1399, 2013.

S. A. Greenberg, Dermatomyositis and type 1 interferons, Current Rheumatology Reports, vol.12, issue.3, pp.198-203, 2010.

S. A. Greenberg, B. W. Higgs, and C. Morehouse, Relationship between disease activity and type 1 interferon-and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis, Genes & Immunity, vol.13, issue.3, pp.207-213, 2012.

R. J. Walsh, S. W. Kong, and Y. Yao, Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis, Arthritis & Rheumatism, vol.56, issue.11, pp.3784-3792, 2007.

S. A. Greenberg, J. L. Pinkus, and G. S. Pinkus, Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis, Annals of Neurology, vol.57, issue.5, pp.664-678, 2005.

S. A. Greenberg, D. Sanoudou, and J. N. Haslett, Molecular profiles of inflammatory myopathies, Neurology, vol.59, issue.8, pp.1170-1182, 2002.

D. Wong, B. Kea, and R. Pesich, Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases, PLoS One, vol.7, issue.1, p.29161, 2012.

C. Cappelletti, F. Baggi, and F. Zolezzi, Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies, Neurology, vol.76, issue.24, pp.2079-2088, 2011.

C. Huard, S. V. Gullà, D. V. Bennett, A. J. Coyle, R. A. Vleugels et al., Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon ? in dermatomyositis, British Journal of Dermatology, vol.176, issue.5, pp.1224-1230, 2017.

Y. Horai, T. Koga, and K. Fujikawa, Serum interferon-? is a useful biomarker in patients with anti-melanoma 13 Journal of Immunology Research differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis, Modern Rheumatology, vol.25, issue.1, pp.85-89, 2014.

W. C. Sun, Y. C. Sun, H. Lin, B. Yan, and G. X. Shi, Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease, British Journal of Dermatology, vol.167, issue.6, pp.1236-1244, 2012.

R. C. Russo, C. C. Garcia, M. M. Teixeira, and F. A. Amaral, The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases, Expert Review of Clinical Immunology, vol.10, issue.5, pp.593-619, 2014.

E. Ferretti, V. Pistoia, and A. Corcione, Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies, Mediators of Inflammation, vol.2014, p.10, 2014.

F. Suzuki, T. Kubota, and Y. Miyazaki, Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity, Arthritis Research & Therapy, vol.14, issue.2, p.48, 2012.

T. Takada, A. Aoki, and K. Asakawa, Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis, Respiratory Medicine, vol.109, issue.9, pp.1174-1180, 2015.

S. M. Ferrari, I. Ruffilli, M. Colaci, A. Antonelli, C. Ferri et al., CXCL10 in psoriasis, Advances in Medical Sciences, vol.60, issue.2, pp.349-354, 2015.

K. Oda, T. Kotani, and T. Takeuchi, Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study, Scientific Reports, vol.7, issue.1, p.1635, 2017.

S. Behfar, G. Hassanshahi, A. Nazari, and H. Khorramdelazad, A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis, Cytokine, vol.110, pp.226-231, 2018.

P. Y. Lee, Y. Li, and Y. Kumagai, Type I interferon modulates monocyte recruitment and maturation in chronic inflammation, The American Journal of Pathology, vol.175, issue.5, pp.2023-2033, 2009.

H. J. Møller, Soluble CD163, Scandinavian Journal of Clinical and Laboratory Investigation, vol.72, issue.1, pp.1-13, 2011.

Y. Enomoto, Y. Suzuki, and H. Hozumi, Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease, Arthritis Research & Therapy, vol.19, issue.1, p.9, 2017.

Q. Peng, Y. L. Zhang, and X. M. Shu, Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue, The Journal of Rheumatology, vol.42, issue.6, pp.979-987, 2015.

K. Shimizu, F. Ogawa, and A. Yoshizaki, Increased serum levels of soluble CD163 in patients with scleroderma, Clinical Rheumatology, vol.31, issue.7, pp.1059-1064, 2012.

H. Kawasumi, Y. Katsumata, and A. Nishino, Association of serum soluble CD163 with polymyositis and dermatomyositis, especially in anti-MDA5 antibody-positive cases, The Journal of Rheumatology, vol.45, issue.7, pp.947-955, 2018.

F. Finkelmeier, Ö. Canli, and A. , High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis, European Journal of Cancer, vol.59, pp.152-159, 2016.

H. Chen, Q. Peng, and H. Yang, Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis, The Journal of Rheumatology, vol.45, issue.6, pp.835-840, 2018.

Z. Yang, Z. Zhang, and F. Lin, Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil-lymphocyte ratios among various systemic autoimmune rheumatic diseases, APMIS, vol.125, issue.10, pp.863-871, 2017.

Y. Ha, J. Hur, and D. J. Go, Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: a retrospective observational study, PLoS One, vol.13, issue.1, p.190411, 2018.

W. Yang, X. Wang, and W. Zhang, Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis, Clinica Chimica Acta, vol.465, pp.11-16, 2017.

J. Zou, Q. Guo, J. Chi, H. Wu, and C. Bao, HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients, Clinical Rheumatology, vol.34, issue.4, pp.707-714, 2015.

S. Zhang, H. Shen, X. Shu, Q. Peng, and G. Wang, Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis, Modern Rheumatology, vol.27, issue.1, pp.122-129, 2017.

C. Wu, Q. Wang, L. He, E. Yang, and X. Zeng, Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: a retrospective case-control study, PLoS One, vol.13, issue.2, p.192491, 2018.

D. J. Go, E. Y. Lee, E. B. Lee, Y. W. Song, M. F. Konig et al., Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a korean retrospective cohort study, Journal of Korean Medical Science, vol.31, issue.3, pp.389-396, 2016.

P. Amerio, C. R. Girardelli, and G. Proietto, Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis, European Journal of Dermatology, vol.12, issue.2, pp.165-169, 2002.

Y. Nawata, K. Kurasawa, and K. Takabayashi, Corticosteroid resistant interstitial pneumonitis in dermatomyositis/-polymyositis: prediction and treatment with cyclosporine, The Journal of Rheumatology, vol.26, issue.7, pp.1527-1533, 1999.

Y. Yamasaki, H. Yamada, and M. Ohkubo, Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan, The Journal of Rheumatology, vol.38, issue.8, pp.1636-1643, 2011.

F. Xiao, J. Z. Tan, X. Y. Xu, and X. F. Wang, Increased levels of HSPA5 in the serum of patients with inflammatory myopathies-preliminary findings, Clinical Rheumatology, vol.34, issue.4, pp.715-720, 2015.

M. Hughes, J. B. Lilleker, A. L. Herrick, and H. Chinoy, Cardiac troponin testing in idiopathic inflammatory myopathies 14 Journal of Immunology Research and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity, Annals of the Rheumatic Diseases, vol.74, issue.5, pp.795-798, 2015.

P. Erlacher, A. Lercher, and J. Falkensammer, Cardiac troponin and ?-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis, Clinica Chimica Acta, vol.306, issue.1-2, pp.27-33, 2001.

T. Gono, Y. Kawaguchi, and M. Hara, Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis, Rheumatology, vol.49, issue.7, pp.1354-1360, 2010.

Y. Xu, C. S. Yang, and Y. J. Li, Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis, Clinical Rheumatology, vol.35, issue.1, pp.113-116, 2016.

M. Ishizuka, R. Watanabe, and T. Ishii, Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors, Modern Rheumatology, vol.26, issue.1, pp.115-120, 2016.

T. Gono, Y. Kawaguchi, and T. Satoh, Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis, Rheumatology, vol.49, issue.9, pp.1713-1719, 2010.

T. Fujisawa, H. Hozumi, and M. Kono, Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases, Respiratory Investigation, vol.55, pp.130-137, 2017.

T. Komiya, N. Negoro, K. Kondo, K. Miura, Y. Hirota et al., Clinical significance of von Willebrand factor in patients with adult dermatomyositis, Clinical Rheumatology, vol.24, issue.4, pp.352-357, 2005.

S. Arai, K. Kurasawa, R. Maezawa, T. Owada, H. Okada et al., Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis, Modern Rheumatology, vol.23, issue.5, pp.872-883, 2013.

H. Ihn, Y. Asano, and M. Kubo, Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease, Rheumatology, vol.41, issue.11, pp.1268-1272, 2002.

F. Chen, X. Lu, X. Shu, Q. Peng, X. Tian et al., Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study, Internal Medicine Journal, vol.45, issue.6, pp.641-647, 2015.

M. Fathi, S. Barbasso, I. E. Helmers, and . Lundberg, KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis, Journal of Internal Medicine, vol.271, issue.6, pp.589-597, 2012.

S. Bandoh, J. Fujita, and Y. Ohtsuki, Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis, Annals of the Rheumatic Diseases, vol.59, issue.4, pp.257-262, 2000.

E. O. Oguz, O. Kucuksahin, and M. Turgay, Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study, Clinical Rheumatology, vol.35, issue.3, pp.663-666, 2016.

G. Kumánovics, T. Minier, J. Radics, L. Pálinkás, T. Berki et al., Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis, Clinical and Experimental Rheumatology, vol.26, issue.3, pp.414-420, 2008.

D. Fujimoto, A. Matsushima, M. Nagao, S. Takakura, and S. Ichiyama, Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases, Modern Rheumatology, vol.23, issue.2, pp.345-350, 2013.

Y. Kanetaka, Y. Kano, K. Hirahara, M. Kurata, and T. Shiohara, Relationship between cytomegalovirus reactivation and dermatomyositis, European Journal of Dermatology, vol.21, issue.2, pp.248-253, 2011.